Martingale Asset Management L P Purchases 1,671 Shares of Iradimed Corporation (NASDAQ:IRMD)

Martingale Asset Management L P raised its position in shares of Iradimed Corporation (NASDAQ:IRMD) by 15.4% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 12,529 shares of the medical equipment provider’s stock after purchasing an additional 1,671 shares during the period. Martingale Asset Management L P’s holdings in Iradimed were worth $630,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. 1620 Investment Advisors Inc. purchased a new position in Iradimed during the 2nd quarter valued at about $25,000. Comerica Bank lifted its holdings in shares of Iradimed by 2,151.6% during the first quarter. Comerica Bank now owns 1,441 shares of the medical equipment provider’s stock valued at $63,000 after purchasing an additional 1,377 shares during the last quarter. Huntington National Bank lifted its holdings in shares of Iradimed by 51.3% during the third quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider’s stock valued at $75,000 after purchasing an additional 504 shares during the last quarter. Gladius Capital Management LP boosted its position in shares of Iradimed by 126.6% in the 3rd quarter. Gladius Capital Management LP now owns 1,727 shares of the medical equipment provider’s stock worth $87,000 after purchasing an additional 965 shares in the last quarter. Finally, Quantbot Technologies LP grew its stake in shares of Iradimed by 83.0% in the 3rd quarter. Quantbot Technologies LP now owns 2,320 shares of the medical equipment provider’s stock worth $117,000 after buying an additional 1,052 shares during the last quarter. 92.34% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Iradimed

In related news, CFO John Glenn sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $54.18, for a total value of $135,450.00. Following the transaction, the chief financial officer now directly owns 4,383 shares of the company’s stock, valued at approximately $237,470.94. This represents a 36.32 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 37.10% of the stock is currently owned by insiders.

Iradimed Trading Down 0.2 %

Shares of NASDAQ:IRMD opened at $53.84 on Tuesday. The stock has a fifty day simple moving average of $51.69 and a two-hundred day simple moving average of $47.27. Iradimed Corporation has a 12-month low of $40.18 and a 12-month high of $57.95. The stock has a market capitalization of $682.09 million, a price-to-earnings ratio of 36.87 and a beta of 0.79.

Iradimed Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, November 25th. Investors of record on Friday, November 15th were paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 1.11%. The ex-dividend date of this dividend was Friday, November 15th. Iradimed’s payout ratio is 41.10%.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.